Fenamates as TRP channel blockers: mefenamic acid selectively blocks TRPM3
BACKGROUND AND PURPOSE Fenamates are N‐phenyl‐substituted anthranilic acid derivatives clinically used as non‐steroid anti‐inflammatory drugs in pain treatment. Reports describing fenamates as tools to interfere with cellular volume regulation attracted our attention based on our interest in the rol...
Saved in:
Published in | British journal of pharmacology Vol. 162; no. 8; pp. 1757 - 1769 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Blackwell Publishing Ltd
01.04.2011
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | BACKGROUND AND PURPOSE Fenamates are N‐phenyl‐substituted anthranilic acid derivatives clinically used as non‐steroid anti‐inflammatory drugs in pain treatment. Reports describing fenamates as tools to interfere with cellular volume regulation attracted our attention based on our interest in the role of the volume‐modulated transient receptor potential (TRP) channels TRPM3 and TRPV4.
EXPERIMENTAL APPROACH Firstly, we measured the blocking potencies and selectivities of fenamates on TRPM3 and TRPV4 as well as TRPC6 and TRPM2 by Ca2+ imaging in the heterologous HEK293 cell system. Secondly, we further investigated the effects of mefenamic acid on cytosolic Ca2+ and on the membrane voltage in single HEK293 cells that exogenously express TRPM3. Thirdly, in insulin‐secreting INS‐1E cells, which endogenously express TRPM3, we validated the effect of mefenamic acid on cytosolic Ca2+ and insulin secretion.
KEY RESULTS We identified and characterized mefenamic acid as a selective and potent TRPM3 blocker, whereas other fenamate structures non‐selectively blocked TRPM3, TRPV4, TRPC6 and TRPM2.
CONCLUSIONS AND IMPLICATIONS This study reveals that mefenamic acid selectively inhibits TRPM3‐mediated calcium entry. This selectivity was further confirmed using insulin‐secreting cells. KATP channel‐dependent increases in cytosolic Ca2+ and insulin secretion were not blocked by mefenamic acid, but the selective stimulation of TRPM3‐dependent Ca2+ entry and insulin secretion induced by pregnenolone sulphate were inhibited. However, the physiological regulator of TRPM3 in insulin‐secreting cells remains to be elucidated, as well as the conditions under which the inhibition of TRPM3 can impair pancreatic β‐cell function. Our results strongly suggest mefenamic acid is the most selective fenamate to interfere with TRPM3 function. |
---|---|
AbstractList | Fenamates are N-phenyl-substituted anthranilic acid derivatives clinically used as non-steroid anti-inflammatory drugs in pain treatment. Reports describing fenamates as tools to interfere with cellular volume regulation attracted our attention based on our interest in the role of the volume-modulated transient receptor potential (TRP) channels TRPM3 and TRPV4.
Firstly, we measured the blocking potencies and selectivities of fenamates on TRPM3 and TRPV4 as well as TRPC6 and TRPM2 by Ca(2+) imaging in the heterologous HEK293 cell system. Secondly, we further investigated the effects of mefenamic acid on cytosolic Ca(2+) and on the membrane voltage in single HEK293 cells that exogenously express TRPM3. Thirdly, in insulin-secreting INS-1E cells, which endogenously express TRPM3, we validated the effect of mefenamic acid on cytosolic Ca(2+) and insulin secretion.
We identified and characterized mefenamic acid as a selective and potent TRPM3 blocker, whereas other fenamate structures non-selectively blocked TRPM3, TRPV4, TRPC6 and TRPM2.
This study reveals that mefenamic acid selectively inhibits TRPM3-mediated calcium entry. This selectivity was further confirmed using insulin-secreting cells. K(ATP) channel-dependent increases in cytosolic Ca(2+) and insulin secretion were not blocked by mefenamic acid, but the selective stimulation of TRPM3-dependent Ca(2+) entry and insulin secretion induced by pregnenolone sulphate were inhibited. However, the physiological regulator of TRPM3 in insulin-secreting cells remains to be elucidated, as well as the conditions under which the inhibition of TRPM3 can impair pancreatic β-cell function. Our results strongly suggest mefenamic acid is the most selective fenamate to interfere with TRPM3 function. BACKGROUND AND PURPOSE Fenamates are N-phenyl-substituted anthranilic acid derivatives clinically used as non-steroid anti-inflammatory drugs in pain treatment. Reports describing fenamates as tools to interfere with cellular volume regulation attracted our attention based on our interest in the role of the volume-modulated transient receptor potential (TRP) channels TRPM3 and TRPV4. EXPERIMENTAL APPROACH Firstly, we measured the blocking potencies and selectivities of fenamates on TRPM3 and TRPV4 as well as TRPC6 and TRPM2 by Ca2+ imaging in the heterologous HEK293 cell system. Secondly, we further investigated the effects of mefenamic acid on cytosolic Ca2+ and on the membrane voltage in single HEK293 cells that exogenously express TRPM3. Thirdly, in insulin-secreting INS-1E cells, which endogenously express TRPM3, we validated the effect of mefenamic acid on cytosolic Ca2+ and insulin secretion. KEY RESULTS We identified and characterized mefenamic acid as a selective and potent TRPM3 blocker, whereas other fenamate structures non-selectively blocked TRPM3, TRPV4, TRPC6 and TRPM2. CONCLUSIONS AND IMPLICATIONS This study reveals that mefenamic acid selectively inhibits TRPM3-mediated calcium entry. This selectivity was further confirmed using insulin-secreting cells. KATP channel-dependent increases in cytosolic Ca2+ and insulin secretion were not blocked by mefenamic acid, but the selective stimulation of TRPM3-dependent Ca2+ entry and insulin secretion induced by pregnenolone sulphate were inhibited. However, the physiological regulator of TRPM3 in insulin-secreting cells remains to be elucidated, as well as the conditions under which the inhibition of TRPM3 can impair pancreatic [beta]-cell function. Our results strongly suggest mefenamic acid is the most selective fenamate to interfere with TRPM3 function. [PUBLICATION ABSTRACT] BACKGROUND AND PURPOSE Fenamates are N‐phenyl‐substituted anthranilic acid derivatives clinically used as non‐steroid anti‐inflammatory drugs in pain treatment. Reports describing fenamates as tools to interfere with cellular volume regulation attracted our attention based on our interest in the role of the volume‐modulated transient receptor potential (TRP) channels TRPM3 and TRPV4. EXPERIMENTAL APPROACH Firstly, we measured the blocking potencies and selectivities of fenamates on TRPM3 and TRPV4 as well as TRPC6 and TRPM2 by Ca2+ imaging in the heterologous HEK293 cell system. Secondly, we further investigated the effects of mefenamic acid on cytosolic Ca2+ and on the membrane voltage in single HEK293 cells that exogenously express TRPM3. Thirdly, in insulin‐secreting INS‐1E cells, which endogenously express TRPM3, we validated the effect of mefenamic acid on cytosolic Ca2+ and insulin secretion. KEY RESULTS We identified and characterized mefenamic acid as a selective and potent TRPM3 blocker, whereas other fenamate structures non‐selectively blocked TRPM3, TRPV4, TRPC6 and TRPM2. CONCLUSIONS AND IMPLICATIONS This study reveals that mefenamic acid selectively inhibits TRPM3‐mediated calcium entry. This selectivity was further confirmed using insulin‐secreting cells. KATP channel‐dependent increases in cytosolic Ca2+ and insulin secretion were not blocked by mefenamic acid, but the selective stimulation of TRPM3‐dependent Ca2+ entry and insulin secretion induced by pregnenolone sulphate were inhibited. However, the physiological regulator of TRPM3 in insulin‐secreting cells remains to be elucidated, as well as the conditions under which the inhibition of TRPM3 can impair pancreatic β‐cell function. Our results strongly suggest mefenamic acid is the most selective fenamate to interfere with TRPM3 function. BACKGROUND AND PURPOSE Fenamates are N‐phenyl‐substituted anthranilic acid derivatives clinically used as non‐steroid anti‐inflammatory drugs in pain treatment. Reports describing fenamates as tools to interfere with cellular volume regulation attracted our attention based on our interest in the role of the volume‐modulated transient receptor potential (TRP) channels TRPM3 and TRPV4. EXPERIMENTAL APPROACH Firstly, we measured the blocking potencies and selectivities of fenamates on TRPM3 and TRPV4 as well as TRPC6 and TRPM2 by Ca 2+ imaging in the heterologous HEK293 cell system. Secondly, we further investigated the effects of mefenamic acid on cytosolic Ca 2+ and on the membrane voltage in single HEK293 cells that exogenously express TRPM3. Thirdly, in insulin‐secreting INS‐1E cells, which endogenously express TRPM3, we validated the effect of mefenamic acid on cytosolic Ca 2+ and insulin secretion. KEY RESULTS We identified and characterized mefenamic acid as a selective and potent TRPM3 blocker, whereas other fenamate structures non‐selectively blocked TRPM3, TRPV4, TRPC6 and TRPM2. CONCLUSIONS AND IMPLICATIONS This study reveals that mefenamic acid selectively inhibits TRPM3‐mediated calcium entry. This selectivity was further confirmed using insulin‐secreting cells. K ATP channel‐dependent increases in cytosolic Ca 2+ and insulin secretion were not blocked by mefenamic acid, but the selective stimulation of TRPM3‐dependent Ca 2+ entry and insulin secretion induced by pregnenolone sulphate were inhibited. However, the physiological regulator of TRPM3 in insulin‐secreting cells remains to be elucidated, as well as the conditions under which the inhibition of TRPM3 can impair pancreatic β‐cell function. Our results strongly suggest mefenamic acid is the most selective fenamate to interfere with TRPM3 function. |
Author | Ullrich, Susanne Riehle, Marc Meyerhof, Wolfgang Straub, Isabelle Krautwurst, Dietmar Ranta, Felicia Harteneck, Christian Klose, Chihab |
Author_xml | – sequence: 1 givenname: Chihab surname: Klose fullname: Klose, Chihab – sequence: 2 givenname: Isabelle surname: Straub fullname: Straub, Isabelle – sequence: 3 givenname: Marc surname: Riehle fullname: Riehle, Marc – sequence: 4 givenname: Felicia surname: Ranta fullname: Ranta, Felicia – sequence: 5 givenname: Dietmar surname: Krautwurst fullname: Krautwurst, Dietmar – sequence: 6 givenname: Susanne surname: Ullrich fullname: Ullrich, Susanne – sequence: 7 givenname: Wolfgang surname: Meyerhof fullname: Meyerhof, Wolfgang – sequence: 8 givenname: Christian surname: Harteneck fullname: Harteneck, Christian |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24021438$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21198543$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkVtLAzEQhYMoWi9_QRbEx9bctskKCipeURTR5zCbndWt22xNWrX_3qytVd_MS0LONzOHM-tk2TUOCUkY7bF49gY9JlW_mwrNepzGX8qY7vc-lkhnISyTDqVUdaOi18h6CANKo6jSVbLGGct0KkWHXJ2hgyGMMSQQkof7u8Q-g3NYJ3nd2Bf0YT8ZYtlClU3AVkUSsEY7rt6wns6gr7obsUlWSqgDbs3vDfJ4dvpwctG9vj2_PDm67to0i94sVWmZlSXlPNdFIQC46ss0B5GpTOQ5z6VQyIpCg7AFKE2BobRcMkFzZQuxQQ5nfUeTfIiFRTf2UJuRr4bgp6aByvxVXPVsnpo3I6iO4WWxwc68gW9eJxjGZtBMvIueDUtlqqTUXEZKzyjrmxA8losJjJp2C2Zg2rBNG7Zpt2C-tmA-Yun2b4eLwu_YI7A7ByBYqEsPzlbhh5OUMyl05A5m3HtV4_TfBszx3UX7Ep_iBKR7 |
CODEN | BJPCBM |
CitedBy_id | crossref_primary_10_1371_journal_pone_0189948 crossref_primary_10_1016_j_cbi_2018_11_018 crossref_primary_10_1016_j_yjmcc_2013_01_019 crossref_primary_10_1007_s00251_011_0570_4 crossref_primary_10_1038_srep05676 crossref_primary_10_1016_j_ccell_2014_09_015 crossref_primary_10_1111_cbdd_13119 crossref_primary_10_1111_bph_12076 crossref_primary_10_3390_ijms23063365 crossref_primary_10_2174_1573407218666220901114151 crossref_primary_10_1016_j_bcp_2012_01_014 crossref_primary_10_4161_23328940_2014_988524 crossref_primary_10_1111_bju_12954 crossref_primary_10_1016_j_ceca_2018_12_009 crossref_primary_10_3390_ijms241310437 crossref_primary_10_1016_j_phrs_2017_07_014 crossref_primary_10_1007_s40199_023_00467_x crossref_primary_10_1016_j_ygcen_2014_10_004 crossref_primary_10_1016_j_mce_2020_111089 crossref_primary_10_3390_cells9122604 crossref_primary_10_1124_mol_119_117952 crossref_primary_10_1371_journal_pone_0117615 crossref_primary_10_1111_j_1471_4159_2011_07441_x crossref_primary_10_1515_hsz_2018_0455 crossref_primary_10_3390_pharmaceutics11090446 crossref_primary_10_1097_j_pain_0000000000000846 crossref_primary_10_1007_s12576_017_0552_x crossref_primary_10_1124_pr_113_008268 crossref_primary_10_1002_jcp_28168 crossref_primary_10_1016_j_molstruc_2024_138812 crossref_primary_10_1016_j_molliq_2022_120502 crossref_primary_10_1016_j_lfs_2012_08_010 crossref_primary_10_1186_s10020_019_0083_4 crossref_primary_10_2217_nnm_2017_0266 crossref_primary_10_1111_j_1476_5381_2011_01649_5_x crossref_primary_10_1152_ajpendo_00337_2014 crossref_primary_10_1124_mol_113_086843 crossref_primary_10_1111_apha_12355 crossref_primary_10_3390_ijms222313133 crossref_primary_10_1016_j_jddst_2015_03_003 crossref_primary_10_1152_jn_00229_2020 crossref_primary_10_1007_s12576_019_00677_6 crossref_primary_10_3390_cells9030685 crossref_primary_10_1155_2022_4684830 crossref_primary_10_1002_prp2_232 crossref_primary_10_1016_j_molstruc_2022_134172 crossref_primary_10_1016_j_pharmthera_2013_01_012 crossref_primary_10_1111_bph_12414 crossref_primary_10_1111_j_1476_5381_2012_02058_x crossref_primary_10_1007_s10787_016_0285_0 crossref_primary_10_1093_cvr_cvu199 crossref_primary_10_1152_ajplung_00426_2015 crossref_primary_10_1186_s40246_020_00258_4 crossref_primary_10_3390_molecules181012012 crossref_primary_10_1016_j_ceca_2011_09_005 crossref_primary_10_1111_bph_14192 crossref_primary_10_1111_1753_0407_12828 crossref_primary_10_1007_s12045_021_1277_y crossref_primary_10_1016_j_ceca_2018_03_005 crossref_primary_10_1016_j_molliq_2023_122230 crossref_primary_10_1016_j_mce_2014_03_001 crossref_primary_10_1016_j_biopha_2017_10_131 crossref_primary_10_1016_j_drudis_2020_09_039 crossref_primary_10_1111_bph_12521 crossref_primary_10_3390_cells9112351 crossref_primary_10_1016_j_jdcr_2018_10_015 crossref_primary_10_1111_bph_12447 crossref_primary_10_1111_bph_12524 crossref_primary_10_1080_23723556_2014_1002712 crossref_primary_10_4161_chan_20719 crossref_primary_10_1016_j_cyto_2017_09_020 crossref_primary_10_1530_JME_12_0237 crossref_primary_10_3389_fcell_2021_635659 |
Cites_doi | 10.1016/j.neuropharm.2004.04.014 10.1074/jbc.M511030200 10.1007/s11064-009-9983-y 10.4049/jimmunol.0902474 10.1016/S1097-2765(02)00448-3 10.1016/0896-6273(89)90069-X 10.1074/jbc.273.17.10402 10.1126/scisignal.2000278 10.2337/diabetes.51.2007.S183 10.1016/S0166-2236(99)01532-5 10.1007/s00424-005-1431-5 10.1007/s10517-008-0144-0 10.1074/jbc.M300945200 10.1124/mol.109.055624 10.1007/s00424-005-1428-0 10.1152/ajpgi.00069.2002 10.1152/ajpcell.00603.2002 10.1074/jbc.M801844200 10.1111/j.1471-4159.2010.06644.x 10.1007/s00125-008-1111-z 10.1016/j.peptides.2007.12.003 10.1113/jphysiol.2005.089888 10.1152/ajprenal.90522.2008 10.2337/diabetes.54.4.1090 10.1016/S0002-9343(98)00091-6 10.1096/fj.07-8110com 10.1124/mol.109.057513 10.1038/sj.emboj.7601083 10.1016/j.ceca.2009.02.006 10.1371/journal.pone.0000827 10.1038/sj.bjp.0706739 10.1096/fj.06-5772com 10.1007/s001250050711 10.1113/jphysiol.2004.063974 10.1074/jbc.M200062200 10.1152/ajpgi.00470.2002 10.1016/S1097-2765(01)00438-5 10.1111/j.1460-9568.2007.05802.x 10.1111/j.1527-3466.2007.00005.x 10.1007/s00125-009-1306-y 10.2174/138161208783330763 10.1007/BF00583543 10.1124/pr.57.4.6 10.1016/S0092-8674(02)00637-2 10.1016/0014-5793(90)80977-Q 10.1111/j.1582-4934.2009.00737.x 10.1085/jgp.200810136 10.1007/s00210-005-1034-x 10.1038/sj.bjp.0707259 10.1016/j.cell.2006.10.038 10.1038/ncb1801 10.1042/bj3580717 10.1073/pnas.0607465103 10.1038/ng1592 10.2170/physiolsci.SC003007 10.1073/pnas.2334624100 10.1016/j.tins.2008.03.002 10.1152/ajpcell.00624.2008 10.1080/004982500237712 |
ContentType | Journal Article |
Copyright | 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society 2015 INIST-CNRS 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society. British Journal of Pharmacology © 2011 The British Pharmacological Society |
Copyright_xml | – notice: 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society – notice: 2015 INIST-CNRS – notice: 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society. – notice: British Journal of Pharmacology © 2011 The British Pharmacological Society |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QP 7TK K9. NAPCQ 5PM |
DOI | 10.1111/j.1476-5381.2010.01186.x |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Calcium & Calcified Tissue Abstracts Neurosciences Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Calcium & Calcified Tissue Abstracts Neurosciences Abstracts |
DatabaseTitleList | MEDLINE ProQuest Health & Medical Complete (Alumni) CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1476-5381 |
EndPage | 1769 |
ExternalDocumentID | 3376187301 10_1111_j_1476_5381_2010_01186_x 21198543 24021438 BPH1186 |
Genre | article Research Support, Non-U.S. Gov't Journal Article Comparative Study |
GroupedDBID | --- .3N .55 .GJ 05W 0R~ 1OC 23N 24P 2WC 31~ 33P 36B 3O- 3SF 3V. 4.4 52U 52V 53G 5GY 6J9 7RV 7X7 8-0 8-1 88E 8AO 8FE 8FH 8FI 8FJ 8R4 8R5 8UM A00 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCUV ABDBF ABPVW ABQWH ABUWG ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFKRA AFPWT AFRAH AFZJQ AHBTC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB AOIJS ATUGU AZBYB AZVAB B0M BAFTC BAWUL BBNVY BENPR BFHJK BHBCM BHPHI BKEYQ BMXJE BPHCQ BRXPI BVXVI C45 CAG CCPQU COF CS3 DCZOG DIK DRFUL DRMAN DRSTM DU5 E3Z EAD EAP EAS EBC EBD EBS ECV EJD EMB EMK EMOBN ENC ESX EX3 F5P FUBAC FYUFA G-S GODZA GX1 H.X HCIFZ HGLYW HMCUK HYE HZ~ J5H KBYEO LATKE LEEKS LH4 LITHE LK8 LOXES LSO LUTES LW6 LYRES M1P M7P MEWTI MK0 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM MY~ N9A NAPCQ NF~ O66 O9- OIG OK1 OVD P2P P2W P4E PQQKQ PROAC PSQYO Q.N Q2X QB0 RIG ROL RPM RWI SJN SUPJJ SV3 TEORI TR2 TUS UKHRP UPT WBKPD WH7 WHWMO WIH WIJ WIK WIN WOHZO WOW WVDHM WXSBR X7M XV2 Y6R YHG ZGI ZXP ZZTAW ~8M ~S- 08R AAJUZ AAPBV AAUGY AAVGM ABCVL ABHUG ABPTK ABWRO ACXME ADAWD ADDAD AFVGU AGJLS IQODW ZA5 CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QP 7TK K9. 5PM |
ID | FETCH-LOGICAL-c5976-c075f9ff022b8dd3aa27645ba39793bb2b437e1dd8a3cda780a1e4c24130b7cd3 |
IEDL.DBID | RPM |
ISSN | 0007-1188 |
IngestDate | Tue Sep 17 21:24:32 EDT 2024 Thu Oct 10 17:06:59 EDT 2024 Fri Aug 23 00:36:29 EDT 2024 Sat Sep 28 07:57:21 EDT 2024 Sun Oct 22 16:08:44 EDT 2023 Sat Aug 24 00:55:11 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 8 |
Keywords | Drug Prostaglandin-endoperoxide synthase Enzyme Enzyme inhibitor non-steroidal anti-inflammatory drugs transient receptor potential Non steroidal antiinflammatory agent pancreatic β-cells Analgesic cationic channel Transient receptor potential channel Mefenamic acid Antipyretic Anthranilic acid derivatives Oxidoreductases Antagonist β Cell fenamate Biological receptor |
Language | English |
License | CC BY 4.0 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c5976-c075f9ff022b8dd3aa27645ba39793bb2b437e1dd8a3cda780a1e4c24130b7cd3 |
Notes | The first two authors contributed equally to the work. |
OpenAccessLink | https://europepmc.org/articles/pmc3081119?pdf=render |
PMID | 21198543 |
PQID | 1545744824 |
PQPubID | 42104 |
PageCount | 13 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3081119 proquest_journals_1545744824 crossref_primary_10_1111_j_1476_5381_2010_01186_x pubmed_primary_21198543 pascalfrancis_primary_24021438 wiley_primary_10_1111_j_1476_5381_2010_01186_x_BPH1186 |
PublicationCentury | 2000 |
PublicationDate | April 2011 |
PublicationDateYYYYMMDD | 2011-04-01 |
PublicationDate_xml | – month: 04 year: 2011 text: April 2011 |
PublicationDecade | 2010 |
PublicationPlace | Oxford, UK |
PublicationPlace_xml | – name: Oxford, UK – name: Basingstoke – name: England – name: London |
PublicationTitle | British journal of pharmacology |
PublicationTitleAlternate | Br J Pharmacol |
PublicationYear | 2011 |
Publisher | Blackwell Publishing Ltd Nature Publishing Group |
Publisher_xml | – name: Blackwell Publishing Ltd – name: Nature Publishing Group |
References | 2009; 45 1997; 40 2005; 371 1990; 268 2005; 451 2002; 51 2002; 277 2010; 184 2008; 31 2008; 145 2003; 278 1998; 273 2009; 13 2009; 52 2006; 20 2008; 29 2010; 114 2006; 25 2007; 2 2002; 108 2006; 281 2006; 127 2005; 37 2007; 21 2007; 25 2007; 26 2003; 285 2003; 284 2010; 77 1989; 2 1989; 413 2002; 9 2000; 23 2004; 47 2009; 297 2008; 14 2009; 133 2008; 10 2009; 296 2008; 51 2007; 57 2008; 283 2009; 34 2009; 75 2007; 151 1995; 47 2005; 567 2000; 30 2005; 54 1998; 104 2006; 148 2009; 2 2004; 558 2003; 100 2005; 57 2006; 103 2001; 358 15961423 - J Physiol. 2005 Aug 15;567(Pt 1):191-213 19454650 - Sci Signal. 2009;2(71):ra23 17666455 - FASEB J. 2007 Dec;21(14):4101-11 19324410 - Cell Calcium. 2009 Jun;45(6):583-8 17927776 - Eur J Neurosci. 2007 Oct;26(8):2119-30 7746266 - Mol Pharmacol. 1995 May;47(5):1006-13 16604090 - Br J Pharmacol. 2006 Jun;148(3):264-73 18220815 - Curr Pharm Des. 2008;14(1):18-31 15843919 - Naunyn Schmiedebergs Arch Pharmacol. 2005 Apr;371(4):307-14 19158345 - Am J Physiol Renal Physiol. 2009 Jun;296(6):F1245-54 20107186 - J Immunol. 2010 Mar 1;184(5):2386-93 11815479 - Diabetes. 2002 Feb;51 Suppl 1:S183-9 12631560 - Am J Physiol Gastrointest Liver Physiol. 2003 Apr;284(4):G604-16 17079490 - Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17079-86 17445088 - Cardiovasc Drug Rev. 2007 Spring;25(1):61-75 15793248 - Diabetes. 2005 Apr;54(4):1090-9 17594756 - J Physiol Sci. 2007 Aug;57(4):249-52 19444608 - Neurochem Res. 2009 Oct;34(10):1738-47 11535132 - Biochem J. 2001 Sep 15;358(Pt 3):717-26 18471901 - Trends Neurosci. 2008 Jun;31(6):287-95 10718119 - Xenobiotica. 2000 Feb;30(2):111-6 12606317 - Am J Physiol Cell Physiol. 2003 Jun;284(6):C1460-7 15895246 - Pflugers Arch. 2005 Oct;451(1):204-11 9626023 - Am J Med. 1998 May;104(5):413-21 11804595 - Mol Cell. 2002 Jan;9(1):163-73 11864597 - Mol Cell. 2002 Feb;9(2):229-31 18226426 - Peptides. 2008 Apr;29(4):613-21 1696554 - FEBS Lett. 1990 Jul 30;268(1):79-82 16601673 - EMBO J. 2006 May 3;25(9):1804-15 18751967 - Diabetologia. 2008 Dec;51(12):2252-62 19382906 - J Cell Mol Med. 2009 Sep;13(9B):3260-7 16940152 - FASEB J. 2006 Sep;20(11):1802-12 17435793 - Br J Pharmacol. 2007 Jun;151(4):483-93 12842831 - Am J Physiol Gastrointest Liver Physiol. 2003 Nov;285(5):G938-48 11827975 - J Biol Chem. 2002 Apr 19;277(16):13569-77 12672799 - J Biol Chem. 2003 Jun 13;278(24):21493-501 17174891 - Cell. 2006 Dec 15;127(6):1123-35 11853675 - Cell. 2002 Feb 8;108(3):421-30 20008516 - Mol Pharmacol. 2010 Mar;77(3):368-77 2516726 - Neuron. 1989 Apr;2(4):1313-23 17786199 - PLoS One. 2007;2(9):e827 19515901 - Am J Physiol Cell Physiol. 2009 Sep;297(3):C493-502 19297520 - Mol Pharmacol. 2009 Jun;75(6):1262-79 10717675 - Trends Neurosci. 2000 Apr;23(4):159-66 9553098 - J Biol Chem. 1998 Apr 24;273(17):10402-10 18978782 - Nat Cell Biol. 2008 Dec;10(12):1421-30 9165220 - Diabetologia. 1997 May;40(5):528-32 14634208 - Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15166-71 16522634 - J Biol Chem. 2006 May 5;281(18):12277-88 19266181 - Diabetologia. 2009 May;52(5):863-72 18818211 - J Biol Chem. 2008 Dec 5;283(49):33942-54 2541404 - Pflugers Arch. 1989 Jan;413(3):287-98 15889307 - Pflugers Arch. 2005 Oct;451(1):264-76 19237589 - J Gen Physiol. 2009 Mar;133(3):245-9 19145282 - Bull Exp Biol Med. 2008 May;145(5):564-8 15924139 - Nat Genet. 2005 Jul;37(7):739-44 16382100 - Pharmacol Rev. 2005 Dec;57(4):427-50 15121803 - J Physiol. 2004 Jul 1;558(Pt 1):75-83 15275834 - Neuropharmacology. 2004 Sep;47(3):450-60 20163522 - J Neurochem. 2010 Aug;114(3):654-65 e_1_2_8_28_1 e_1_2_8_24_1 e_1_2_8_47_1 e_1_2_8_26_1 e_1_2_8_49_1 e_1_2_8_3_1 e_1_2_8_5_1 e_1_2_8_7_1 e_1_2_8_9_1 e_1_2_8_20_1 e_1_2_8_43_1 e_1_2_8_22_1 e_1_2_8_45_1 e_1_2_8_41_1 e_1_2_8_60_1 e_1_2_8_17_1 e_1_2_8_19_1 Kankaanranta H (e_1_2_8_29_1) 1995; 47 e_1_2_8_13_1 e_1_2_8_36_1 e_1_2_8_59_1 e_1_2_8_15_1 e_1_2_8_38_1 e_1_2_8_57_1 e_1_2_8_32_1 e_1_2_8_55_1 e_1_2_8_11_1 e_1_2_8_34_1 e_1_2_8_53_1 e_1_2_8_51_1 e_1_2_8_30_1 e_1_2_8_25_1 e_1_2_8_46_1 e_1_2_8_27_1 e_1_2_8_48_1 e_1_2_8_2_1 e_1_2_8_4_1 e_1_2_8_6_1 e_1_2_8_8_1 e_1_2_8_21_1 e_1_2_8_42_1 e_1_2_8_23_1 e_1_2_8_44_1 e_1_2_8_40_1 e_1_2_8_61_1 e_1_2_8_18_1 e_1_2_8_39_1 e_1_2_8_14_1 e_1_2_8_35_1 e_1_2_8_16_1 e_1_2_8_37_1 e_1_2_8_58_1 e_1_2_8_10_1 e_1_2_8_31_1 e_1_2_8_56_1 e_1_2_8_12_1 e_1_2_8_33_1 e_1_2_8_54_1 e_1_2_8_52_1 e_1_2_8_50_1 |
References_xml | – volume: 273 start-page: 10402 year: 1998 end-page: 10410 article-title: Characterization of a Ca release‐activated nonselective cation current regulating membrane potential and [Ca ] oscillations in transgenically derived beta‐cells publication-title: J Biol Chem – volume: 29 start-page: 613 year: 2008 end-page: 621 article-title: Regulation of stretch‐activated ANP secretion by chloride channels publication-title: Peptides – volume: 77 start-page: 368 year: 2010 end-page: 377 article-title: Simple 2,4 diacylphloroglucinols as TRPC6 activators – identification of a novel pharmacophore publication-title: Mol Pharmacol – volume: 75 start-page: 1262 year: 2009 end-page: 1279 article-title: Pharmacology of vanilloid transient receptor potential cation channels publication-title: Mol Pharmacol – volume: 20 start-page: 1802 year: 2006 end-page: 1812 article-title: TRPV4‐mediated regulation of epithelial permeability publication-title: FASEB J – volume: 283 start-page: 33942 year: 2008 end-page: 33954 article-title: Specific TRPC6 channel activation, a novel approach to stimulate keratinocyte differentiation publication-title: J Biol Chem – volume: 14 start-page: 18 year: 2008 end-page: 31 article-title: Vanilloid transient receptor potential cation channels: an overview publication-title: Curr Pharm Des – volume: 567 start-page: 191 year: 2005 end-page: 213 article-title: Characterization of a proton‐activated, outwardly rectifying anion channel publication-title: J Physiol – volume: 37 start-page: 739 year: 2005 end-page: 744 article-title: TRPC6 is a glomerular slit diaphragm‐associated channel required for normal renal function publication-title: Nat Genet – volume: 127 start-page: 1123 year: 2006 end-page: 1135 article-title: TRPV1 sensory neurons control β cell stress and islet inflammation in autoimmune diabetes publication-title: Cell – volume: 9 start-page: 163 year: 2002 end-page: 173 article-title: LTRPC2 Ca ‐permeable channel activated by changes in redox status confers susceptibility to cell death publication-title: Mol Cell – volume: 371 start-page: 307 year: 2005 end-page: 314 article-title: Function and pharmacology of TRPM cation channels publication-title: Naunyn Schmiedebergs Arch Pharmacol – volume: 2 start-page: 1313 year: 1989 end-page: 1323 article-title: Molecular characterization of the Drosophila trp locus: a putative integral membrane protein required for phototransduction publication-title: Neuron – volume: 40 start-page: 528 year: 1997 end-page: 532 article-title: Identification of four trp1 gene variants murine pancreatic beta‐cells publication-title: Diabetologia – volume: 268 start-page: 79 year: 1990 end-page: 82 article-title: Flufenamic acid, mefenamic acid and niflumic acid inhibit single nonselective cation channels in the rat exocrine pancreas publication-title: FEBS Lett – volume: 451 start-page: 204 year: 2005 end-page: 211 article-title: The mammalian melastatin‐related transient receptor potential cation channels: an overview publication-title: Pflügers Arch – volume: 9 start-page: 229 year: 2002 end-page: 231 article-title: A unified nomenclature for the superfamily of TRP cation channels publication-title: Mol Cell – volume: 296 start-page: F1245 year: 2009 end-page: F1254 article-title: TRPMLs: in sickness and in health publication-title: Am J Physiol Renal Physiol – volume: 151 start-page: 483 year: 2007 end-page: 493 article-title: Non‐steroidal anti‐inflammatory drugs increase insulin release from beta cells by inhibiting ATP‐sensitive potassium channels publication-title: Br J Pharmacol – volume: 285 start-page: G938 year: 2003 end-page: G948 article-title: Fundamental role of ClC‐3 in volume‐sensitive Cl channel function and cell volume regulation in AGS cells publication-title: Am J Physiol Gastrointest Liver Physiol – volume: 25 start-page: 1804 year: 2006 end-page: 1815 article-title: TRPM2 activation by cyclic ADP‐ribose at body temperature is involved in insulin secretion publication-title: EMBO J – volume: 51 start-page: S183 issue: 1 year: 2002 end-page: S189 article-title: TRP genes: candidates for nonselective cation channels and store‐operated channels in insulin‐secreting cells publication-title: Diabetes – volume: 104 start-page: 413 year: 1998 end-page: 421 article-title: Cyclooxygenase‐1 and cyclooxygenase‐2 selectivity of widely used nonsteroidal anti‐inflammatory drugs publication-title: Am J Med – volume: 52 start-page: 863 year: 2009 end-page: 872 article-title: Niflumic acid‐sensitive ion channels play an important role in the induction of glucose‐stimulated insulin secretion by cyclic AMP in mice publication-title: Diabetologia – volume: 25 start-page: 61 year: 2007 end-page: 75 article-title: N‐(p‐amylcinnamoyl)anthranilic acid (ACA): a phospholipase A inhibitor and TRP channel blocker publication-title: Cardiovasc Drug Rev – volume: 145 start-page: 564 year: 2008 end-page: 568 article-title: Effects of fenamate on inhibitory postsynaptic currents in Purkinje's cells publication-title: Bull Exp Biol Med – volume: 2 start-page: e827 year: 2007 article-title: Arterial response to shear stress critically depends on endothelial TRPV4 expression publication-title: PLoS ONE – volume: 358 start-page: 717 year: 2001 end-page: 726 article-title: A diacylglycerol‐activated Ca channel in PC12 cells (an adrenal chromaffin cell line) correlates with expression of the TRP‐6 (transient receptor potential) protein publication-title: Biochem J – volume: 2 start-page: ra23 year: 2009 article-title: TRPM2 functions as a lysosomal Ca ‐release channel in beta cells publication-title: Sci Signal – volume: 47 start-page: 450 year: 2004 end-page: 460 article-title: Flufenamic acid is a pH‐dependent antagonist of TRPM2 channels publication-title: Neuropharmacology – volume: 57 start-page: 249 year: 2007 end-page: 252 article-title: A novel inhibitor of hypertonicity‐induced cation channels in HeLa cells publication-title: J Physiol Sci – volume: 31 start-page: 287 year: 2008 end-page: 295 article-title: Neuronal TRP channels: thermometers, pathfinders and life‐savers publication-title: Trends Neurosci – volume: 30 start-page: 111 year: 2000 end-page: 116 article-title: Fenamates and the potent inhibition of human liver phenol sulphotransferase publication-title: Xenobiotica – volume: 21 start-page: 4101 year: 2007 end-page: 4111 article-title: Hyperforin – a key constituent of St. John's wort specifically activates TRPC6 channels publication-title: FASEB J – volume: 57 start-page: 427 year: 2005 end-page: 450 article-title: International Union of Pharmacology. XLIX. Nomenclature and structure‐function relationships of transient receptor potential channels publication-title: Pharmacol Rev – volume: 45 start-page: 583 year: 2009 end-page: 588 article-title: TRPC channel lipid specificity and mechanisms of lipid regulation publication-title: Cell Calcium – volume: 277 start-page: 13569 year: 2002 end-page: 13577 article-title: Activation of TRPV4 channels (hVRL‐2/mTRP12) by phorbol derivatives publication-title: J Biol Chem – volume: 284 start-page: C1460 year: 2003 end-page: C1467 article-title: Contribution of chloride channels to volume regulation of cortical astrocytes publication-title: Am J Physiol Cell Physiol – volume: 133 start-page: 245 year: 2009 end-page: 249 article-title: TRPA1 and cold transduction: an unresolved issue? publication-title: J Gen Physiol – volume: 284 start-page: G604 year: 2003 end-page: G616 article-title: TRPC5 as a candidate for the nonselective cation channel activated by muscarinic stimulation in murine stomach publication-title: Am J Physiol Gastrointest Liver Physiol – volume: 184 start-page: 2386 year: 2010 end-page: 2393 article-title: Transient receptor potential melastatin 2 is required for lipopolysaccharide‐induced cytokine production in human monocytes publication-title: J Immunol – volume: 108 start-page: 421 year: 2002 end-page: 430 article-title: Molecular basis for species‐specific sensitivity to ‘hot’ chili peppers publication-title: Cell – volume: 114 start-page: 654 year: 2010 end-page: 665 article-title: TRPM3 is expressed in sphingosine‐responsive myelinating oligodendrocytes publication-title: J Neurochem – volume: 23 start-page: 159 year: 2000 end-page: 166 article-title: From worm to man: three subfamilies of TRP channels publication-title: Trends Neurosci – volume: 13 start-page: 3260 year: 2009 end-page: 3267 article-title: H O ‐induced Ca influx and its inhibition by N‐(p‐amylcinnamoyl)anthranilic acid in the beta‐cells: involvement of TRPM2 channels publication-title: J Cell Mol Med – volume: 451 start-page: 264 year: 2005 end-page: 276 article-title: Polycystins: polymodal receptor/ion‐channel cellular sensors publication-title: Pflügers Arch – volume: 297 start-page: C493 year: 2009 end-page: C502 article-title: Evidence that TRPM7 is required for breast cancer cell proliferation publication-title: Am J Physiol Cell Physiol – volume: 558 start-page: 75 year: 2004 end-page: 83 article-title: Functional characterization of a Ca ‐activated non‐selective cation channel in human atrial cardiomyocytes publication-title: J Physiol – volume: 278 start-page: 21493 year: 2003 end-page: 21501 article-title: Molecular and functional characterization of the melastatin‐related cation channel TRPM3 publication-title: J Biol Chem – volume: 54 start-page: 1090 year: 2005 end-page: 1099 article-title: Serum‐ and glucocorticoid‐inducible kinase 1 (SGK1) mediates glucocorticoid‐induced inhibition of insulin secretion publication-title: Diabetes – volume: 281 start-page: 12277 year: 2006 end-page: 12288 article-title: Anion channels, including ClC‐3, are required for normal neutrophil oxidative function, phagocytosis, and transendothelial migration publication-title: J Biol Chem – volume: 413 start-page: 287 year: 1989 end-page: 298 article-title: The nonselective cation channel in the basolateral membrane of rat exocrine pancreas. Inhibition by 3′,5‐dichlorodiphenylamine‐2‐carboxylic acid (DCDPC) and activation by stilbene disulfonates publication-title: Pflügers Arch – volume: 148 start-page: 264 year: 2006 end-page: 273 article-title: Inhibition of TRPM2 cation channels by N‐(p‐amylcinnamoyl)anthranilic acid publication-title: Br J Pharmacol – volume: 34 start-page: 1738 year: 2009 end-page: 1747 article-title: Modulation of glutamate and glycine transporters by niflumic, flufenamic and mefenamic acids publication-title: Neurochem Res – volume: 103 start-page: 17079 year: 2006 end-page: 17086 article-title: Podocin and MEC‐2 bind cholesterol to regulate the activity of associated ion channels publication-title: Proc Natl Acad Sci USA – volume: 51 start-page: 2252 year: 2008 end-page: 2262 article-title: Calcium elevation in mouse pancreatic beta cells evoked by extracellular human islet amyloid polypeptide involves activation of the mechanosensitive ion channel TRPV4 publication-title: Diabetologia – volume: 26 start-page: 2119 year: 2007 end-page: 2130 article-title: Small‐conductance Cl channels contribute to volume regulation and phagocytosis in microglia publication-title: Eur J Neurosci – volume: 47 start-page: 1006 year: 1995 end-page: 1013 article-title: Flufenamic and tolfenamic acids inhibit calcium influx in human polymorphonuclear leukocytes publication-title: Mol Pharmacol – volume: 10 start-page: 1421 year: 2008 end-page: 1430 article-title: Transient receptor potential M3 channels are ionotropic steroid receptors in pancreatic beta cells publication-title: Nat Cell Biol – volume: 100 start-page: 15166 year: 2003 end-page: 15171 article-title: TRPM5 is a transient Ca ‐activated cation channel responding to rapid changes in [Ca ] publication-title: Proc Natl Acad Sci USA – ident: e_1_2_8_24_1 doi: 10.1016/j.neuropharm.2004.04.014 – ident: e_1_2_8_40_1 doi: 10.1074/jbc.M511030200 – ident: e_1_2_8_17_1 doi: 10.1007/s11064-009-9983-y – ident: e_1_2_8_61_1 doi: 10.4049/jimmunol.0902474 – ident: e_1_2_8_39_1 doi: 10.1016/S1097-2765(02)00448-3 – ident: e_1_2_8_38_1 doi: 10.1016/0896-6273(89)90069-X – ident: e_1_2_8_50_1 doi: 10.1074/jbc.273.17.10402 – ident: e_1_2_8_33_1 doi: 10.1126/scisignal.2000278 – ident: e_1_2_8_46_1 doi: 10.2337/diabetes.51.2007.S183 – ident: e_1_2_8_21_1 doi: 10.1016/S0166-2236(99)01532-5 – ident: e_1_2_8_8_1 doi: 10.1007/s00424-005-1431-5 – ident: e_1_2_8_10_1 doi: 10.1007/s10517-008-0144-0 – ident: e_1_2_8_14_1 doi: 10.1074/jbc.M300945200 – ident: e_1_2_8_58_1 doi: 10.1124/mol.109.055624 – ident: e_1_2_8_30_1 doi: 10.1007/s00424-005-1428-0 – ident: e_1_2_8_34_1 doi: 10.1152/ajpgi.00069.2002 – ident: e_1_2_8_43_1 doi: 10.1152/ajpcell.00603.2002 – ident: e_1_2_8_41_1 doi: 10.1074/jbc.M801844200 – ident: e_1_2_8_25_1 doi: 10.1111/j.1471-4159.2010.06644.x – ident: e_1_2_8_4_1 doi: 10.1007/s00125-008-1111-z – ident: e_1_2_8_18_1 doi: 10.1016/j.peptides.2007.12.003 – ident: e_1_2_8_32_1 doi: 10.1113/jphysiol.2005.089888 – ident: e_1_2_8_45_1 doi: 10.1152/ajprenal.90522.2008 – ident: e_1_2_8_55_1 doi: 10.2337/diabetes.54.4.1090 – ident: e_1_2_8_7_1 doi: 10.1016/S0002-9343(98)00091-6 – ident: e_1_2_8_35_1 doi: 10.1096/fj.07-8110com – ident: e_1_2_8_36_1 doi: 10.1124/mol.109.057513 – ident: e_1_2_8_54_1 doi: 10.1038/sj.emboj.7601083 – ident: e_1_2_8_3_1 doi: 10.1016/j.ceca.2009.02.006 – ident: e_1_2_8_23_1 doi: 10.1371/journal.pone.0000827 – ident: e_1_2_8_31_1 doi: 10.1038/sj.bjp.0706739 – ident: e_1_2_8_49_1 doi: 10.1096/fj.06-5772com – volume: 47 start-page: 1006 year: 1995 ident: e_1_2_8_29_1 article-title: Flufenamic and tolfenamic acids inhibit calcium influx in human polymorphonuclear leukocytes publication-title: Mol Pharmacol contributor: fullname: Kankaanranta H – ident: e_1_2_8_51_1 doi: 10.1007/s001250050711 – ident: e_1_2_8_16_1 doi: 10.1113/jphysiol.2004.063974 – ident: e_1_2_8_60_1 doi: 10.1074/jbc.M200062200 – ident: e_1_2_8_27_1 doi: 10.1152/ajpgi.00470.2002 – ident: e_1_2_8_19_1 doi: 10.1016/S1097-2765(01)00438-5 – ident: e_1_2_8_9_1 doi: 10.1111/j.1460-9568.2007.05802.x – ident: e_1_2_8_22_1 doi: 10.1111/j.1527-3466.2007.00005.x – ident: e_1_2_8_11_1 doi: 10.1007/s00125-009-1306-y – ident: e_1_2_8_56_1 doi: 10.2174/138161208783330763 – ident: e_1_2_8_12_1 doi: 10.1007/BF00583543 – ident: e_1_2_8_6_1 doi: 10.1124/pr.57.4.6 – ident: e_1_2_8_28_1 doi: 10.1016/S0092-8674(02)00637-2 – ident: e_1_2_8_13_1 doi: 10.1016/0014-5793(90)80977-Q – ident: e_1_2_8_2_1 doi: 10.1111/j.1582-4934.2009.00737.x – ident: e_1_2_8_5_1 doi: 10.1085/jgp.200810136 – ident: e_1_2_8_20_1 doi: 10.1007/s00210-005-1034-x – ident: e_1_2_8_37_1 doi: 10.1038/sj.bjp.0707259 – ident: e_1_2_8_47_1 doi: 10.1016/j.cell.2006.10.038 – ident: e_1_2_8_59_1 doi: 10.1038/ncb1801 – ident: e_1_2_8_53_1 doi: 10.1042/bj3580717 – ident: e_1_2_8_26_1 doi: 10.1073/pnas.0607465103 – ident: e_1_2_8_48_1 doi: 10.1038/ng1592 – ident: e_1_2_8_42_1 doi: 10.2170/physiolsci.SC003007 – ident: e_1_2_8_44_1 doi: 10.1073/pnas.2334624100 – ident: e_1_2_8_52_1 doi: 10.1016/j.tins.2008.03.002 – ident: e_1_2_8_15_1 doi: 10.1152/ajpcell.00624.2008 – ident: e_1_2_8_57_1 doi: 10.1080/004982500237712 |
SSID | ssj0014775 |
Score | 2.3863776 |
Snippet | BACKGROUND AND PURPOSE Fenamates are N‐phenyl‐substituted anthranilic acid derivatives clinically used as non‐steroid anti‐inflammatory drugs in pain... Fenamates are N-phenyl-substituted anthranilic acid derivatives clinically used as non-steroid anti-inflammatory drugs in pain treatment. Reports describing... BACKGROUND AND PURPOSE Fenamates are N‐phenyl‐substituted anthranilic acid derivatives clinically used as non‐steroid anti‐inflammatory drugs in pain... BACKGROUND AND PURPOSE Fenamates are N-phenyl-substituted anthranilic acid derivatives clinically used as non-steroid anti-inflammatory drugs in pain... |
SourceID | pubmedcentral proquest crossref pubmed pascalfrancis wiley |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 1757 |
SubjectTerms | Acids Animals Anti-Inflammatory Agents, Non-Steroidal - pharmacology Biological and medical sciences Calcium - metabolism cationic channel fenamate Fenamates - pharmacology HEK293 Cells Humans Insulin Insulin - metabolism Insulin-Secreting Cells - metabolism Medical sciences Mefenamic Acid - pharmacology Mice non‐steroidal anti‐inflammatory drugs Pancreas pancreatic β‐cells Pharmacology. Drug treatments Research Papers transient receptor potential TRPC Cation Channels - antagonists & inhibitors TRPM Cation Channels - antagonists & inhibitors TRPV Cation Channels - antagonists & inhibitors |
Title | Fenamates as TRP channel blockers: mefenamic acid selectively blocks TRPM3 |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1476-5381.2010.01186.x https://www.ncbi.nlm.nih.gov/pubmed/21198543 https://www.proquest.com/docview/1545744824 https://pubmed.ncbi.nlm.nih.gov/PMC3081119 |
Volume | 162 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fa9swED6aPg3G2O957YIeRp_qpooUSdnbVtaFQoYZKeRNSLLEQhMvzB0s_311st3UbA9jbwZLGPmTfN_57r4DeE8lsyYa0lwwLnNUN8H4rsuDUMEG5riTWO88_ypm1_xqOVkewKSrhUlJ-86uzqr15qxafU-5lduNG3V5YqNifsGiHaN0OhrAQDLWueht6IBL2bQtQPVDqlQ_fYdLkcczTtukrjhAJC1qFDpTE8565unx1tTxTYWmxcXfOOifqZQPKW6yUZdP4UlLLsnHZhHP4MBXz-GkaNSpd6dksS-2qk_JCSn2utW7F3AVd6zZIPckpiaLbwXBquDKr4mNFu8m8sQPZOODTy3siXGrktSpi078YK53zaA0b85ewvXl58XFLG9bLeQuehQid5E5hGkI0aJbVZbMmLEUfGINhv2YtWPLmfS0LJVhrjRSnRvquUtBOStdyV7BYfWj8m-AKM6n0js7Pg8oRq-sYk7YUk5dsN4zlgHt3rDeNooa-qEnIoVGgDQCpBNA-ncGwx4U9xMxNoQN3DM47rDR7SGsNbJDGd3PMc_gdQPTfmKLdwayB-D9AJTd7t-JuzHJb7e7LwORoP7nRehPxQyv3v73I4_gUfNLGxOHjuHw9ucv_y5yols7hMGXJR2mk3AHC68Gig |
link.rule.ids | 230,315,733,786,790,891,27955,27956,53825,53827 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VcgAJ8X4ESvEB9dTsNrFje7lBRbWUbhWhLerNsh1brLobVmQrsfx6_Ei6DXAAbpHsUWR_duZzZvwNwOuMYSWdI00pJiz16iY-vqtTS7lVFmuimb_vPDml4zNyfF6cb0HR3YUJSftazQb1fDGoZ19CbuVyoYddntiwnBxi58eybDS8ATfdfs2L7pDeBg8IY7Fwgdc_zDjvJ_AQRlNnlbVpXa4DDWrUXuqMFwT3HNSdpWzcXNlY5OJPLPT3ZMrrJDd4qaN78LkbX0xOuRhcrtRA__hF-vGfJ-A-3G15K3obmx_Alqkfwl4Zha_X-2i6ucfV7KM9VG4ksdeP4NhtBrnwtBbJBk0_lchfOK7NHCnnTC8cBX2DFsb6TjONpJ5VqAkFety3eL6OnYLdBD-Gs6P308Nx2lZxSLU7rNBUO1JiR9Y6sqB4VWEpc0ZJoaSPKGKlckUwM1lVcYl1JRk_kJkhOsT7FNMVfgLb9dfaPAPECRkxo1V-YL3OPVcca6oqNtJWGYNxAlkHnVhGsQ5x_ZDDqPDIC4-8CMiL7wns9jC-MvRhJ18bPoGdDnTR7u9GeOLJ3Mk2Jwk8jfhvDNuFlADrrYyrDl7Ru9_icA7K3i2uCdCwhv56EOJdOfZPz__7la_g1ng6OREnH04_voDb8c-5z0_age3Vt0vz0lGvldoNG-0nqvsnhg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED_BkBAS4nsQGMMPaE9Lu8Su7fIGg6oMOkWokyZeLH-Kam2oSCdR_npsJ1kb4AHtLVLuFDl3l_s5d_4dwOuMYSV9Ik0pJiwN7CahvqtTR7lTDmuiWTjvPDml4zNycj443xr1FZv2tZr1yvmiV86-xd7K5UL32z6xfjE5xj6PZdmwvzSufxNu-ZjNWbtRbwoIhLF6eEHgQMw47zbxEEZTr5U1rV1egEZG6kB3xgcEd5LU3aWs_Pty9aCLfyHRvxsqt4FuzFSj-_C1XWPdoHLRu1ypnv71B_3jtV7CA7jX4Ff0thZ5CDds-QgOipoAe32IppvzXNUhOkDFhhp7_RhOfFDIRYC3SFZo-qVA4eBxaedI-aR64aHoG7SwLgjNNJJ6ZlAVB_X4b_J8XQtFvQl-AmejD9PjcdpMc0i137TQVHtw4obOedCguDFYypxRMlAyVBaxUrkimNnMGC6xNpLxI5lZomPdTzFt8C7slN9L-wwQJ2TIrFb5kQt891xxrKkybKidshbjBLLWfGJZk3aI7c0OoyJYXwTri2h98TOB_Y6drxRD-SnMiE9grzW8aOK8EgGAMr_DzUkCT2sf2Cg2zpQA63jHlUBg9u7e8baODN-NbROg0Y_-exHiXTEOV8-v_chXcLt4PxKfP55-egF36h_ooU1pD3ZWPy7tS4_AVmo_xtpvDRoqBg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Fenamates+as+TRP+channel+blockers%3A+mefenamic+acid+selectively+blocks+TRPM3&rft.jtitle=British+journal+of+pharmacology&rft.au=Klose%2C+Chihab&rft.au=Straub%2C+Isabelle&rft.au=Riehle%2C+Marc&rft.au=Ranta%2C+Felicia&rft.date=2011-04-01&rft.pub=Blackwell+Publishing+Ltd&rft.issn=0007-1188&rft.eissn=1476-5381&rft.volume=162&rft.issue=8&rft.spage=1757&rft.epage=1769&rft_id=info:doi/10.1111%2Fj.1476-5381.2010.01186.x&rft_id=info%3Apmid%2F21198543&rft.externalDBID=PMC3081119 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-1188&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-1188&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-1188&client=summon |